

AA734

6

CLAIMS

gk  
C2  
1. A method for detecting a de-myelinating disease or spongiform encephalopathy in mammals which comprises testing a biological sample obtained from the mammal for IgA antibodies which bind to an *Acinetobacter* antigen.

2. A method according to claim 1, in which the *Acinetobacter* is one which presents to the mammal an antigen which exhibits molecular mimicry with the myelin of the mammal.

sub  
C2  
3. A method according to claim <sup>1</sup>~~1 or 2~~, in which the antibodies are indicative of prior infection by *Acinetobacter calcoaceticus*.

sub  
C2  
4. A method according to claim <sup>1</sup>~~1, 2, or 3~~, in which the antibodies tested for are antibodies which bind to an epitope present in or derived from the *Acinetobacter* species or to a prepared peptide sequence corresponding thereto.

sub  
B2  
5. A method according to <sup>claim 1</sup>~~any of claims 1 to 4~~, in which the disease tested for is bovine spongiform encephalopathy.

6. A method according to <sup>claim 1</sup>~~any of claims 1 to 4~~, in which the disease tested for is multiple sclerosis in humans.

7. A method according to <sup>claim 1</sup>~~any of claims 1 to 4~~, in which the disease tested for is Creutzfeldt-Jacob disease in humans.

M 14:02:00

7

Claim 1

a 8. A method according to ~~any of the preceding claims~~ in which antibodies are assayed and a positive result is indicated by levels of antibodies at least about two standard deviations above that of control samples.

Claim 1

9. A test kit for use with a method according to ~~any of claims 1 to 8~~, in which the test antigen is the whole *Acinetobacter* organism or at least one prepared peptide sequence corresponding to an *Acinetobacter* epitope, said test kit including a secondary antibody against the human, bovine, or other mammalian IgA.

10. A method according to claim ~~1, 2, or 3~~, in which the antibodies tested for are antibodies which bind to a peptide sequence conformationally similar to an *Acinetobacter* epitope.

11. A method according to claim 10, in which the epitope is the peptide sequence ISRFAWGEV.

12. A method according to claim 10, in which the epitope contains the peptide sequence RFSAWGAE.

10  
13. A test kit for use with a method according to claim ~~10, 11, or 12~~, in which the test antigen is a peptide sequence which is conformationally sufficiently similar to an *Acinetobacter* epitope to bind to the relevant antibodies, said test kit including a secondary antibody against the human, bovine, or other mammalian IgA.

14 17.02.00

15. A test kit according to claim 9, ~~or according to claim 13 or 14~~, in which the secondary antibody is a rabbit anti-human IgA or rabbit anti-bovine IgA.

15. A test kit according to claim 9, ~~or according to claim 13 or 14~~, in which the secondary antibody is a rabbit anti-human IgA or rabbit anti-bovine IgA.

AMENDED SHEET